Jessica Altamirano, MD
Infectious Disease · Miami Gardens, FLNPI 1518169721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,620 of the $92,352 with a category attached, or 61.3%. 14 manufacturers reported payments, led by Gilead at 58.1% of the total. 2025 is the largest year on record at $39,529, more than ten times the $1,871 reported in 2019. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $203.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54K
- Janssen Products, LP$19K
- Viiv Healthcare Company$17K
- Johnson & Johnson$1K
- Merck$600
- Napo Pharmaceuticals Inc$175
- plus $238 from 8 others
Across 11 payments — averaging $37,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$414K
- Viiv Healthcare Company$4K
What the payments were for
- Consulting fees$20,65022%
- Speaking & faculty fees$56,62061%
- Travel & lodging$4,9315%
- Food & beverage$9,92011%
- Education$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 148 | $53,643 |
| Janssen Products, LP | 21 | $19,188 |
| Viiv Healthcare Company | 170 | $17,318 |
| Johnson & Johnson(2 entities) | 68 | $1,190 |
| Merck | 26 | $600 |
| Napo Pharmaceuticals Inc | 7 | $175 |
| Theratechnologies Inc. | 3 | $67 |
| GSK | 3 | $51 |
| Exact Sciences | 2 | $36 |
| AbbVie | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Emmaus Medical, Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,352 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 183 | $707,561 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 90 | $408,901 |
| DovatoDolutegravir Sodium/Lamivudine | 63 | $177,545 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 35 | $130,645 |
| TivicayDolutegravir Sodium | 45 | $106,217 |
| JulucaDolutegravir/Rilpivirine | 28 | $95,041 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $77,775 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $62,425 |
| PrezcobixDarunavir/Cobicistat | 25 | $59,410 |
| PrezistaDarunavir | 15 | $28,360 |
| Darunavir | 34 | $25,408 |
| IsentressRaltegravir Potassium | 11 | $20,339 |
| Ritonavir | 39 | $3,177 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 24 | $71 |
| Rosuvastatin Calcium | 16 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $53,643 | $847,762236 claims |
| Janssen Products, LPSymtuza | $19,188 | $408,90190 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca | $17,318 | $378,803136 claims |
| Johnson & JohnsonPrezcobix | $1,190 | $59,41025 claims |
| Janssen Scientific Affairs, LLCPrezista | $12 | $28,36015 claims |
| MerckIsentress | $600 | $20,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami Gardens
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.